13134-38-8

Basic information

• Product Name: (PyrazinaMine, 3,6- diMethyl
• Synonyms: (PyrazinaMine, 3,6- diMethyl;2-PYRAZINAMINE, 3,6-DIMETHYL-;2-Amino-3,6-dimethylpyrazine;3,6-DiMethyl-2-pyrazinaMine;2-Amino-3,6-dimethylpyrazine 3,6-Dimethylpyrazin-2-amine;3,6-Dimethylpyrazinamine;3-Amino-2,5-dimethylpyrazine;2-Amino-3,6-dimethylpyrazine 96%
• CAS NO: 13134-38-8
• Molecular Formula: C₆H₉N₃
• Molecular Weight: 123.15576
• Mol File: 13134-38-8.mol
• Article Data: 7

Chemical Properties

• Melting Point: 111-113℃ (benzene )
• Boiling Point: 119℃ (10 Torr)
• Flash Point: 124.5±13.1℃
• Appearance: /
• Density: 1.112±0.06 g/cm3 (20 ºC 760 Torr)
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• PKA: 3.85±0.10(Predicted)
• CAS DataBase Reference: (PyrazinaMine, 3,6- diMethyl(CAS DataBase Reference)
• NIST Chemistry Reference: (PyrazinaMine, 3,6- diMethyl(13134-38-8)
• EPA Substance Registry System: (PyrazinaMine, 3,6- diMethyl(13134-38-8)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• WGK Germany: 3
• Hazardous Substances Data: 13134-38-8(Hazardous Substances Data)

Usage

General Description

Pyrazinamine, 3,6-dimethyl is a synthetic, organic compound that belongs to the family of Pyrazines. These are polycyclic aromatic compounds containing a pyrazine ring, which is a six-membered aromatic heterocycle made up of two nitrogen atoms and four carbon atoms, substituted with two methyl groups at positions 3 and 6. The chemical properties of this compound have not been well-studied, and very little is known about its potential uses or hazards.

Upstream product

• 123-32-0 2,5-dimethyl-pyrazine 
• 83505-98-0 2-azido-3,6-dimethylpyrazine 
• 95-89-6 2,5-dimethyl-3-chloropyrazine 

Downstream Products

• 10212-66-5 N-(3,6-dimethyl-pyrazin-2-yl)-benzamide 
• 873377-13-0 N-acetyl-sulfanilic acid-(3,6-dimethyl-pyrazin-2-ylamide) 
• 5433-89-6 sulfanilic acid-(3,6-dimethyl-pyrazin-2-ylamide) 
• 1351515-90-6 1-amino-3,6-dimethylpyrazin-2(1H)-iminium 2,4,6-trimethylbenzenesulfonate 
• 1201689-16-8 (5,8-dimethyl-[1,2,4]triazolo[1,5-a]pyrazin-2-ylmethyl)-triphenyl-phosphonium chloride 
• 1447715-68-5 [1-(5,8-dimethyl-[1,2,4]triazolo[1,5-a]pyrazin-2-yl)ethyl]triphenyl phosphonium chloride 
• 1451735-27-5 5,8-dimethyl-2-[1-methyl-2-(1-methyl-4-phenyl-1H-imidazol-2-yl)-ethyl]-[1,2,4]triazolo[1,5a]pyrazine 
• 1451735-35-5 5,8-dimethyl-2-[(E)-1-methyl-2-(1-methyl-4-phenyl-1H-imidazol-2-yl)-vinyl][1,2,4]triazolo[1,5a]pyrazine 

Relevant articles and documents

FUSED TRIAZOLE DERIVATIVES AS PHOSPHODIESTERASE 10A INHIBITORS

Compounds of the general formula (I), wherein one of X1 and X2 represents N, and the other one of X1 and X2 represents -C(CH3), A represents unsubstituted or substituted 5-, 6-or 10-membered aryl or h

NOVEL COMPOUNDS

The present invention is directed to novel retinoid-related orphan receptor gamma (RORγ) modulators, processes for their preparation, pharmaceutical compositions containing these modulators, and their use in the treatment of inflammatory, metabolic and autoimmune diseases mediated by RORγ.

HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF

Provided herein are heteroaryl compounds, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. In one embodiment, the compounds provided herein are useful for the treatment, prevention, and/or management of various disorders, such as CNS disorders and metabolic disorders, including, but not limited to, e.g., neurological disorders, psychosis, schizophrenia, obesity, and diabetes